All relevant data are within the manuscript and its Supporting Information files.

Introduction {#sec001}
============

Antibiotics can be used as "insurance" against livestock losses to disease, challenging the control of antibiotic use and antibiotic residues in food products. This situation is common in many low-income countries where the burden of infectious diseases drives the demand for antibiotics. In these settings, informal food markets are supplied with animals or animal products produced under limited antibiotic regulations, lack of enforcement of drug withdrawal periods, and absence of residue testing programs. For milk, depending on the drug formulation, the recommended withdrawal periods for ampicillin and oxytetracycline are 2 and 4 days \[[@pone.0233413.ref001]\], respectively. Adherence to these recommendations can be very expensive for persons living at the economic margins.

The presence of antibiotic residues in household and commercially available milk has been reported in East Africa \[[@pone.0233413.ref002]--[@pone.0233413.ref008]\]. β-lactams and oxytetracyclines, which are commonly used to treat mastitis and livestock respiratory diseases in this region, can trigger hyper-allergenic reactions in people if their residue concentration in consumed milk is sufficient \[[@pone.0233413.ref009]--[@pone.0233413.ref011]\]; maximum residue limits for amoxicillin and oxytetracycline are 4 ppb and 100 ppb, respectively \[[@pone.0233413.ref012]\]. Furthermore, for milk that is contaminated with pathogenic bacteria, antibiotic residues can favor the growth of antibiotic-resistant strains that may be directly ingested by the consumer. This is in addition to the risk posed when contaminated milk is exposed to temperatures that are optimal for bacterial growth (37--42°C) \[[@pone.0233413.ref013]\].

In densely populated urban settlements, poor environmental hygiene and improper milk storage can contribute to milk contamination and proliferation of bacteria within milk, respectively. We estimated the prevalence of antibiotic residues in milk sold in Kibera, an informal settlement located within Nairobi. Kibera is serviced by a formal market which supplies pasteurized milk in sealed plastic bags or through automated vending machines, and by an informal market (small-scale farms) which supplies unpasteurized milk \[[@pone.0233413.ref014]\]. Given that most households in Kibera have no means to refrigerate milk, they are likely to encounter conditions that are ideal for growth of high-density populations of antibiotic-resistant bacteria in stored milk. To assess the degree to which this problem may arise in communities like Kibera, we collected pasteurized and unpasteurized milk samples from local vendors and tested them for antibiotic residues and bacterial counts (colony forming units per ml; CFU/ml). Bacterial counts were log transformed (base 10).

Materials and methods {#sec002}
=====================

Sampling {#sec003}
--------

During September 2015, milk samples were purchased from formal and informal vendors serving Soweto and Gatwekera villages in Kibera. Milk samples were purchased from vendors trading within a 200 m radius from households that were participating in a longitudinal study on antimicrobial resistance. Sample collection occurred over a 2-week period, primarily between 9 and 11 a.m. Once collected, samples were transported on ice to a microbiology laboratory located in Kibera within two hours of collection.

Residue testing {#sec004}
---------------

All samples were transferred into sterile 50-ml conical tubes and tested for the presence of β-lactam and tetracycline residues by using IDEXX SNAP kits (IDEXX Laboratories Inc., Maine, USA) following manufacturer instructions \[[@pone.0233413.ref015],[@pone.0233413.ref016]\]. These commercial test kits provide rapid presence/absence results at a sensitivity approaching 50 ppb and cross-react with a variety of β-lactam and tetracycline analogues, respectively \[[@pone.0233413.ref017]\]. Residue testing was completed on the day of sample collection and results were recorded as "positive" or "negative" for presence of the respective antibiotic residue. Milk spiked with tetracycline and ampicillin at 20 μg/ml (20 ppm) was used as the positive control for the SNAP kits.

Bacteriology {#sec005}
------------

The total number of presumptive *E*. *coli* and antibiotic-resistant *E*. *coli* was also determined for each sample on the day of sample collection. Unpasteurized milk samples were serially diluted (10-fold) with phosphate-buffered saline and 50 μl of the 10^0^ to 10^−3^ dilution was plated onto MacConkey agar plates with no antibiotic, with ampicillin (32 μg/ml) and with tetracycline (16 μg/ml). The latter two plates selected for ampicillin-resistant (Amp^R^) or tetracycline-resistant (Tet^R^) *E*. *coli*, respectively. Plates were incubated at 37°C for 18--24 hours and presumptive *E*. *coli* identified by colony morphology \[[@pone.0233413.ref018]\]. Plates with 10--100 colonies were selected for colony counts, and the colony-forming units (CFU) per mL recorded for each sample. When fewer than 10 colonies were observed at the 10^0^ dilution, all visible colonies were counted. If colony density greatly exceeded 100 colonies at the 10^−3^ dilution, the refrigerated left-over sample was diluted further and re-plated. Prior to sample collection, five pasteurized, packaged milk samples were purchased and plated as described, and no bacteria were detected. Consequently, no additional pasteurized milk samples were tested for bacterial growth.

Minimum detection sensitivity {#sec006}
-----------------------------

To determine the analytic detection sensitivity of the methods employed in this study, we serially diluted (10-fold) 2.5 x 10^9^ CFU of *E*. *coli* with whole pasteurized milk. Four dilutions (10^0^ to 10^−3^) were plated onto MacConkey agar using the spread plating technique and incubated at 37°C for 18 hours. The minimum number of detectable *E*. *coli* was determined from the plate containing the highest milk dilution with visible colonies.

Data analysis {#sec007}
-------------

A Wilcoxon rank-sum test was used to compare the number of unpasteurized samples relative to the presence of antibiotic residues and antibiotic-resistant *E*. *coli*. To compare the correlation between counts (CFU/ml) of Amp^R^ and Tet^R^ *E*. *coli*, zero counts were transformed to a random number between 0 and 650 (uniform distribution) to account for detection sensitivity limits, and all values were log-transformed (base 10) before the analysis. Statistics were calculated by using Stata software (ver. 15.1, StatCorp LLC, College Station, TX).

Results {#sec008}
=======

In total, 96 milk samples were collected, 75 of which were purchased from shops (pasteurized) and 21 from mobile vendors (unpasteurized). Pasteurized samples were mainly sold in 250--500 mL sealed plastic packages, while unpasteurized samples were measured in a 250 mL glass and transferred into thin plastic bags ([Fig 1](#pone.0233413.g001){ref-type="fig"}). One pasteurized milk sample was excluded from the analysis due to fermentation. Ten of the total 95 milk samples (10.5%) tested positive for antibiotic residues, including seven (7.4%) which were positive for β-lactam residues and three (3.2%) for tetracycline residues; none were positive for both. Residues were more likely to be present in unpasteurized samples (5/21, 23.8%) compared with pasteurized samples (5/74, 6.8%); *P =* 0.039. Among the 21 unpasteurized samples, 14 samples (66.7%) contained detectable numbers of presumptive *E*. *coli* colonies (mean 3.5 Log~10~ CFU/ml) out of which 92.8% (13/14) and 50% (7/14) were positive for Amp^R^--(mean 3.2 Log~10~ CFU/ml) and Tet^R^--*E*. *coli* (mean 3.1 Log~10~ CFU/ml), respectively. No *E*. *coli* were recovered from seven of the unpasteurized samples ([S1](#pone.0233413.s001){ref-type="supplementary-material"} and [S2](#pone.0233413.s002){ref-type="supplementary-material"} Tables).

![Examples of milk samples tested; (a) unpackaged/unpasteurized milk and (b) packaged/pasteurized milk (modified version of original packaging; used for illustrative purposes only).](pone.0233413.g001){#pone.0233413.g001}

The minimum detection sensitivity of our methods was 2.8 Log~10~ CFU/ml. Unpasteurized milk samples had *E*. *coli* counts ranging from 1.1--7.5 Log~10~ CFU/ml, while the counts of Amp^R^ *E*. *coli* or Tet^R^ *E*. *coli* ranged from 1.3--6.9 and 2.0--6.7 Log~10~ CFU/ml, respectively ([Fig 2](#pone.0233413.g002){ref-type="fig"}). There was a significant correlation between the number of Amp^R^ and Tet^R^ *E*. *coli* (*r*^2^ = 0.81, *P* = 0.001). The presence of antibiotic residues was not associated with the number of antibiotic-resistant *E*. *coli* (*P* \> 0.5 for all comparisons).

![Total, Amp^R^ and Tet^R^ *E*. *coli* counts (Log~10~ CFU/mL) for individual unpasteurized milk samples (n = 21).\
No bacterial growth was observed across the three media types for samples 2, 7, 17--21. An explanation for the variation shown below the detection limit is provided under the methods section.](pone.0233413.g002){#pone.0233413.g002}

Discussion {#sec009}
==========

Unpasteurized milk has a potential role in disseminating both pathogens and antibiotic-resistant bacteria to people through several mechanisms. First, antibiotic-resistant bacteria can be directly acquired through ingestion of milk contaminated with these bacteria \[[@pone.0233413.ref019]\]. In this study, 67% of unpasteurized milk samples contained *E*. *coli*, most of which were resistant to ampicillin and/or tetracycline. Further, the strong correlation between the number of Amp^R^ and Tet^R^ *E*. *coli* suggests that these were likely multi-drug resistant strains. Consuming just one cup of milk contaminated with 10^6^ antibiotic-resistant bacteria per ml can result in inoculation with over 10^8^ bacteria, a problem that can be prevented through pasteurization. Nevertheless, where storage is poor post-pasteurization hygiene problems (e.g., use of contaminated containers) can lead to re-contamination. Beyond transmission of antibiotic-resistant bacteria, livestock serve as reservoirs for multiple gastrointestinal pathogens of public health concern.^22^ Ingestion of these pathogens in unpasteurized milk can increase antibiotic use by the consumer, contributing to the emergence of AMR \[[@pone.0233413.ref020]--[@pone.0233413.ref022]\].

Antibiotic residues in milk can select for antibiotic-resistant bacteria within milk itself, which can then be transmitted directly to people through ingestion. It was unclear from this study if this mechanism is important since we found no correlation between the presence of antibiotic residues and that of antibiotic-resistant *E*. *coli*. This may be a limitation of the small sample size considered in this study. Additionally, being that the samples collected in this study were obtained from vendors rather than individual households, they unlikely represent the full range of storage conditions that may exist within Kibera. Fortunately, most of the milk samples (n = 75) collected in this study were pasteurized, perhaps reflecting a higher prevalence of vendors selling pasteurized than unpasteurized milk in Kibera, and a relative affordability of packaged pasteurized milk. Further, the relationship between antibiotic residues and antibiotic-resistant bacteria is dose-dependent \[[@pone.0233413.ref023]\]. The SNAP tests used in this study simply allowed a "positive" or "negative" classification of samples without quantifying the concentration of residues within milk samples classified as "positive". Additional work is needed to quantify antibiotic residues within milk to re-examine their relationship with antibiotic-resistant bacteria.

The consumption of antibiotic residues in milk can potentially select for antibiotic-resistant bacteria within a consumer's gut microflora, a mechanism that has yet to be fully investigated \[[@pone.0233413.ref024]\]. A study that administered a therapeutic dose (10 mg/kg) of oxytetracycline intramuscularly to groups of cows reported antibiotic residue concentrations in milk as high as 1.92 μg/ml. This concentration falls within a range that can selectively favor antibiotic-resistant *E*. *coli* \[[@pone.0233413.ref025]\] and is likely sufficient to do so after ingestion of contaminated milk depending on rates of absorption and dissipation \[[@pone.0233413.ref026]\]. In this study, the prevalence of β-lactam (7%) and tetracycline (3%) positive samples was 9 and 4 times higher than the prevalence of residues (0.8%) reported in U.S. milk in 2012 \[[@pone.0233413.ref027]\]. Residues were observed in both pasteurized and unpasteurized samples, indicating that residue control needs to be focused on all producers, although there is a clear trend towards a lower prevalence of contamination for pasteurized products. In Kenya, boiling is commonly used when consumers prepare milk for consumption, but this practice does not appear to affect presence of residues in milk \[[@pone.0233413.ref028]\].

Aside from the potential antibiotic-resistance consequences of having antibiotic residues in milk, ingestion of these residues can cause allergic reactions, carcinogenicity, hepatotoxicity, bone marrow toxicity, and reproductive disorders \[[@pone.0233413.ref009],[@pone.0233413.ref011],[@pone.0233413.ref028]--[@pone.0233413.ref031]\]. Limiting antibiotic residues in milk will require a multimodal approach including education of producers, stricter oversight of antibiotic sales and withdrawal times (in milk, ampicillin and oxytetracycline withdrawal times are 2 days and 4 days following injection, respectively \[[@pone.0233413.ref001]\]), stronger surveillance of residues and AMR in food animal products, and increased awareness and concern of AMR and its pathways of dissemination amongst policy makers and veterinary officials \[[@pone.0233413.ref003],[@pone.0233413.ref032]\].

There were several limitations to this study. Firstly, the SNAP tests used to detect antibiotic residues (presence/absence) required a subjective interpretation of the results; we classified samples as negative unless the test was very clearly positive. Secondly, we cannot conclusively tell how the milk affects consumers, who are likely to process milk prior to consumption or consume it later after purchasing, given that milk was tested soon after its purchase from vendors. It is also possible that antibiotic residues may have a greater effect on microbial contaminants the longer the consumer stores milk. We purchased and tested milk directly from the vendor and did not consider consumer behaviors and practices. We also acknowledge that sample collection was opportunistic, rather than random, which could introduce bias to these findings.

Supporting information {#sec010}
======================

###### Study data for all milk samples collected.

(XLSX)

###### 

Click here for additional data file.

###### Study data for unpasteurized milk samples only.

(XLSX)

###### 

Click here for additional data file.

The authors would like to thank the field team working within Kibera for collecting the milk samples for this project.
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Reviewer \#1: The manuscript by Brown et al presents results of public health importance. They reported antibiotic residues in 10% of ready to consume milk, and majority of unpasteurized milk samples containing high bacterial load including antibiotic resistant bacteria. Although the study is of great interest, the methods are vaguely presented, results are inconsistent, poorly presented and discussed. Please see general and specific comments below.

Abstract

Line 32: please change "hypoallergenic" to "hyperallergenic" as used in the body of the manuscript (line 61). I suggest using the more general term (without the specific type) "allergic".

Line 43-44 and elsewhere in the text: would you present the CFU/ml values in log10 scale?

Line 43-44 and elsewhere in the text: how these percentages (note that in the text it was mentioned 92% for ampicillin line 131) were calculated? Please clearly state this in the materials and methods. How is it possible to calculate resistant fraction obtained on media supplemented with antibiotics from total bacterial count obtained from plain media? This biases towards the numerator as we already select for the resistant population, simply the methods by which the two values were determined are different. For the stated proportions replica platting would be appropriate. See more comment on this below.

Line 45: How did you arrive at the conclusion of "no evidence"? Please show statistical analysis.

Introduction

Please add literature (perhaps between lines 61 and 62) on the maximum residue level (MRL) allowed in milk for the beta-lactam and oxytetracycline.

Line 71: replace" with" by "which"

Materials and methods

Line 89: Please add manufacturer's information (company, city, State or Country)

Line 99-100: what dilution(s) were plated? This is important since you used direct plating, too numerous to count indicates high bacterial load; on the other hand, most samples can be BDL if contamination is low which should be expected in milk (and water) and normally filtration is also used for detection.

Line 113: please correct the degree sign as 37°C

Why your analytical sensitivity of 650 CFU/ml is high? How many colonies per plate was your cut-off to count? Did you count 1CFU/plate and consider such a sample as positive, or how did you deal with? Please clarify your methods.

Data analysis

Was the "random number" substitution a form of imputation? Please state. Also discuss if this method would introduce a bias, for not adding it to observations with enumerable values.

What log scale was used? If log10 state so.

Results

Line 129-130: please provide statistical significance for the difference.

Line 130-131: as commented above please clarify how the percentages were calculated.

"Among unpasteurized samples, 14 samples (67%) contained presumptive E. coli colonies out of which 92.8% and 50% were positive for AmpR-- and TetR--E. coli, respectively." This is inconsistent with what was presented in the abstract: Line 42-44: "One third of unpasteurized samples (8/21, 38%) contained detectable numbers of presumptive E. coli (mean 9.2 x 106 CFU/ml) and of these, 87% were positive for ampicillin- (3.7 x 106 CFU/ml) and 50% for tetracycline-resistant E. coli (1.4 x 106/ml)."

Line 130: what does the phrase "contained presumptive" indicate and how was it derived? Is it enumeration positive (i.e. above BDL)? Please clarify.

Please mention that E. coli (wild or resistant strains) were not observed on enumeration plate or are BDL.

Line 133-134: please also include the mean values (preferably log10) for each media type used.

Line 136: given you have only tested two antibiotic classes, I would replace "multidrug-resistance" with co-selection.

Line 137: change "residuals" to residues.

Fig: Please use log10 scale since most studies report that way. In the title please add "by media type" to avoid confusion with drug residues. For the milk samples with no plot observations (example \#2, 7, 17-21), were the three types of bacteria (generic, Amp resistant and Tet resistant E. coli) absent across the three media types? Please state. What do ME and MD mean? Please state.

Discussion
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Line 146-148: again, you did not test individual colonies of the total E. coli you obtained on plain media to give you proportion resistant, which would only be possible through replica platting. Rather you isolated the three bacterial strains independently. So, present all your results on sample basis throughout the manuscript.

Line 161: should read "represent"

Reviewer \#2: This is a modest but well executed study that examines the presence of antibiotic residues in milk from vendors in Nairobi and seeks to determine if there are any correlations between presence of residues, and presence of resistant bacteria. Essentially looking to inform the question of whether the residues, if present, might enrich for antibiotic resistant bacteria in the milk. There are a number of experimental design limitations in the current study that impact the interpretation of the results. However the authors clearly acknowledge these, and provide informative discussion points so that readers who might not be familiar with the details of antibiotic resistance in this system will be able to understand the limitations. There is a need to better understand antibiotic resistance in African countries, and this study provides information that informs question related to food safety and antibiotic resistance in a culturally relevant setting. The data need to be made available in supporting information.
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Comment 1

We understand that you purchased milk from local markets for this study. In your Methods section, please provide additional details regarding the source of this material.

• Please provide the geographic coordinates and names of the purchase locations (e.g., shops, vendors), if available.

\>\> We have provided a study description for this community, but we cannot supply the requested geographic coordinates. This is because such coordinates are not available for the mobile vendors who sell raw milk or even for the formal vendors that typically erect a shop that is later moved or abandoned within a matter of months. As such, reporting such coordinates would not help in the replication of this study

• Further details about the purchased items (e.g., quantity, source origin) to ensure reproducibility of the analyses.

\>\> These details have now been included. We have also included a figure (not Fig 1) to illustrate the packaging of these milk samples. We did not collect data regarding the source origin of the milk samples we purchased.

Comment 2

Thank you for including the following funding information within the acknowledgements section of your manuscript; \"This work was funded by the Paul G. Allen School for Global Animal Health, and by the Washington State University College of Veterinary Medicine Summer Research Fellowship Program. \"

• Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: \"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.\"

\>\> Funding information deleted from the acknowledgement section

Comment 3

The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

\>\> The dataset has been provided as part of supporting information.

Comment 4

The reviewers observe merit in the study, but there are significant concerns relative to the methods presented and the statistical analyses conducted.

• The authors need to clearly state how the study was conducted and the analyses that were done.

\>\> Specific questions about the methods and analyses have been clarified in the revision as indicated under each specific comment below.

• Furthermore, the data presentation could be improved, and statistical analyses need to be conducted properly as noted by Reviewer 1.

\>\> We believe that we have addressed the clarity issues that were noted by the reviewer. Please note that the reviewer mistakenly concluded that we calculated the proportion of resistant bacteria by making a ratio of the CFU count from agar plates without antibiotic and agar plates with antibiotic. All our comparisons are on a sample basis (presence or absence of detectable antibiotic-resistant bacteria) as the reviewer suggests should have been done. We report total counts from the plates, but not a proportion of the plate without antibiotic. It is unclear to us why this confusion may have occurred.

Comment 5

Reviewer \#1: The manuscript by Brown et al presents results of public health importance. They reported antibiotic residues in 10% of ready to consume milk, and majority of unpasteurized milk samples containing high bacterial load including antibiotic resistant bacteria.

• Although the study is of great interest, the methods are vaguely presented, results are inconsistent, poorly presented and discussed. Please see general and specific comments below.

• Abstract

o Line 32: please change "hypoallergenic" to "hyperallergenic" as used in the body of the manuscript (line 61). I suggest using the more general term (without the specific type) "allergic".

\>\> we have replaced this term with "immunogenic"

o Line 43-44 and elsewhere in the text: would you present the CFU/ml values in log10 scale?

\>\> This has now been addressed.

o Line 43-44 and elsewhere in the text: how these percentages (note that in the text it was mentioned 92% for ampicillin line 131) were calculated? Please clearly state this in the materials and methods.

\>\> The calculation of all percentages has been clarified by indicating the specific counts that form the numerators and denominators.

o How is it possible to calculate resistant fraction obtained on media supplemented with antibiotics from total bacterial count obtained from plain media? This biases towards the numerator as we already select for the resistant population, simply the methods by which the two values were determined are different. For the stated proportions replica platting would be appropriate. See more comment on this below.

\>\>As above, we are not sure why the reviewer drew this conclusion about the methods. There is no text describing calculation of a resistant fraction in terms of bacterial numbers. All proportion values that we report are relative to the proportion of positive or negative samples, not bacterial counts. For bacterial counts, we calculated total bacterial counts based on the corresponding plates from which these counts were made.

o Line 45: How did you arrive at the conclusion of "no evidence"? Please show statistical analysis.

\>\> We have revised this statement to read: "We found no relationship between the presence of antibiotic residues and the abundance of antibiotic-resistant E. coli".

• Introduction

o Please add literature (perhaps between lines 61 and 62) on the maximum residue level (MRL) allowed in milk for the beta-lactam and oxytetracycline.

\>\> This information has been added

o Line 71: replace" with" by "which"

\>\> Corrected. Thank you.

• Materials and methods

o Line 89: Please add manufacturer's information (company, city, State or Country)

\>\> This information has been added

o Line 99-100: what dilution(s) were plated? This is important since you used direct plating, too numerous to count indicates high bacterial load; on the other hand, most samples can be BDL if contamination is low which should be expected in milk (and water) and normally filtration is also used for detection.

\>\> The dilutions that were plated have been included in the revision.

o Line 113: please correct the degree sign as 37°C

\>\> This has been corrected. Thank you.

o Why your analytical sensitivity of 650 CFU/ml is high?

\>\> We agree that this value is higher than what would be expected with, for example, water, but it is an empirically derived value. We surmise that the count seems high because bacteria clump with milk components and thus a single colony from a milk sample potentially represents more than one bacterium. For the same reason, filtration would not have remedied this issue. Please note that if such clumping occurred, we consider this effect to be similar across all samples

o How many colonies per plate was your cut-off to count?

\>\> We primarily chose the dilution that gave us at least 10 colonies per plate. Counts below this threshold were only included for undiluted/neat milk samples. These thresholds have been included in the methods.

o Did you count 1CFU/plate and consider such a sample as positive, or how did you deal with? Please clarify your methods.

\>\> There was only one instance where one colony was observed in plate containing an undiluted milk sample. This plate had 5 colonies in the Mac agar without antibiotics, 1 in the Amp+ plate and no colonies in the Tet+ plate.

• Data analysis

o Was the "random number" substitution a form of imputation? Please state.

\>\> This was based on a random number drawn from a uniform distribution. This has been added to the manuscript.

o Also discuss if this method would introduce a bias, for not adding it to observations with enumerable values.

\>\> We used this method to avoid issues that arise when transforming small numbers to a log scale (negative axis values) and because it acknowledges that we should not treat a negative value as truly negative given that there is a minimum analytic sensitivity of this assay. Not adding this value has no consequence to statistical comparisons that are made on a sample basis (positive vs. negative). Failure to add a similar randomly selected number between 0 and 650 would potentially bias the final counts to a lower value, but this is unlikely to be significant as the counts increase on a log scale.

o What log scale was used? If log10 state so.

\>\> This has now been addressed.

• Results

o Line 129-130: please provide statistical significance for the difference.

\>\> This information has been added

o Line 130-131: as commented above please clarify how the percentages were calculated.

"Among unpasteurized samples, 14 samples (67%) contained presumptive E. coli colonies out of which 92.8% and 50% were positive for AmpR-- and TetR--E. coli, respectively." This is inconsistent with what was presented in the abstract: Line 42-44: "One third of unpasteurized samples (8/21, 38%) contained detectable numbers of presumptive E. coli (mean 9.2 x 106 CFU/ml) and of these, 87% were positive for ampicillin- (3.7 x 106 CFU/ml) and 50% for tetracycline-resistant E. coli (1.4 x 106/ml)."

\>\>This was an error that has now been corrected.

o Line 130: what does the phrase "contained presumptive" indicate and how was it derived? Is it enumeration positive (i.e. above BDL)? Please clarify.

\>\>Please recall that we identified E. coli based only on colony morphology. While this works the majority of the time (cite your JMM paper), it is not perfect. We use "presumptive" as a qualifier to acknowledge this uncertainty.

o Please mention that E. coli (wild or resistant strains) were not observed on enumeration plate or are BDL.

\>\> This has now been addressed.

o Line 133-134: please also include the mean values (preferably log10) for each media type used.

\>\> This information has now been added.

o Line 136: given you have only tested two antibiotic classes, I would replace "multidrug-resistance" with co-selection.

\>\> This has been amended to make it clear that there is a probability that these were multi-drug resistant strains, even though we did not test for other resistance types. Additionally, we have moved this bit of statement to the discussion section to make it clear that this is our interpretation of this finding.

o Line 137: change "residuals" to residues.

\>\> This has been corrected. Thank you

o Fig: Please use log10 scale since most studies report that way.

\>\> This has now been addressed.

o In the title please add "by media type" to avoid confusion with drug residues.

\>\> We have changed values to log scale. We changed the title by inserting the word "detected" to eliminate confusion (although we are not certain that we follow the reviewer's meaning with respect to the original title).

o For the milk samples with no plot observations (example \#2, 7, 17-21), were the three types of bacteria (generic, Amp resistant and Tet resistant E. coli) absent across the three media types? Please state.

\>\> This information has been included in the figure caption.

o What do ME and MD mean? Please state.

\>\> This information has been included in the figure caption.

• Discussion

o Line 146: please insert "unpasteurized" before "milk" and elsewhere in the discussion. Pasteurization removes this issue.

\>\> This has been amended as suggested.

o Line 146-148: again, you did not test individual colonies of the total E. coli you obtained on plain media to give you proportion resistant, which would only be possible through replica platting. Rather you isolated the three bacterial strains independently. So, present all your results on sample basis throughout the manuscript.

\>\> we are uncertain why the reviewer is making this argument since our results are presented on a sample basis. We report total counts with and without antibiotic in the agar, but we did not calculate a proportion of resistant bacteria based on these values.

o Line 161: should read "represent"

\>\> This has been corrected. Thank you
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